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ﬁbrosis, supporting its usefulness in clinical practice.
42 M.M. Maher et al.Liver biopsy;
Keratins
Aims: To evaluate the role of CK-18 as a non invasive marker in diagnosis of NASH and its
usefulness in correlation with disease severity in Egyptian patients.
Patients and methods: 90 subjects were divided into 3 groups: group I: including 30 patients with
NASH, group II: including 30 patients with NAFL, and group III: including 30 healthy subjects as
control. Diagnosis of NASH and its discrimination from NAFL was done by liver biopsy. CK-18
level in plasma was measured for all subjects using ELISA.
Results: CK-18 was signiﬁcantly elevated in patients of group I in comparison to group II and
III patients, with mean ± SD: 460 ± 279, 167 ± 56 and 149 ± 57, respectively, andP value: 0.001.
The (ROC) curve diagnostic performance of CK18 in diagnosis of NASH shows: cutoff value of
>240 U/L, with sensitivity 76.7%, speciﬁcity 95.0%. Ck-18 was found to correlate with disease
severity assessed by NAS scoring system with P value: 0.001.
Conclusion: Measurement of CK18 in NASH is a useful screening, diagnostic and staging bio-
marker.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Nonalcoholic fatty liver disease (NAFLD) encompasses a wide
spectrum of conditions associated with over accumulation of
fat in the liver ranging from nonalcoholic fatty liver disease
NAFLD to nonalcoholic steatohepatitis (NASH) and cirrhosis
[1].
Although NAFL typically follows a benign non progressive
clinical course, NASH is a potentially serious condition; as
many as 25% of patients may progress to cirrhosis and expe-
rience complications of portal hypertension, liver failure, and
hepato-cellular carcinoma [2].
It was suggested that progression from NAFL to NASH
and to advanced ﬁbrosis results from two distinct events; ﬁrst,
insulin resistance (IR) leading to the accumulation of fat
within hepatocytes, and second, mitochondrial reactive oxygen
species causing lipid peroxidation and cytokine induction [3].
Cytokeratins are proteins of keratin-containing intermedi-
ate ﬁlaments found in the intracytoplasmic cytoskeleton of epi-
thelial tissue. In 2006 a new systematic nomenclature for
keratins was created and now the proteins previously called
‘‘cytokeratins’’ are simply called keratins [4].
When hepatocytes are chronically exposed to oxidative
stress and toxic substances, they become ballooned, accumu-
late fat, show a disruption in the keratin intermediate ﬁlament
network, and form Mallory bodies [5]. A Mallory body is com-
posed of abnormally phosphorylated and cross-linked kera-
tins, such as cytokeratin (CK) 8 and 18 and stress-induced
proteins [6].
Since hepatocytes containing Mallory bodies are suscepti-
ble to apoptosis, so those levels of Mallory body-associated
proteins released from hepatocytes into peripheral blood
may be increased in NASH patients and change in accordance
with disease activity [7].
At present, liver biopsy remains the only reliable and the
‘‘gold standard’’ way of diagnosing NASH, grading the sever-
ity of liver damage and for assessing ﬁbrosis and architectural
alterations [8]. Liver biopsy is an invasive procedure that car-
ries a risk of complications. It is an imperfect tool; due to sam-
pling errors, biopsy size (5–30 mm) and intra- and inter-
observer variability, it is now agreed that biopsy is an ‘‘imper-
fect Gold Standard diagnostic tool’’ [9]. Hence new simple andnon-invasive test that both accurately distinguishes NASH
from NAFLD and determines the stage and grade of the dis-
ease is urgently needed [10].
In the current study we investigated the role of serum cyto-
keratin 18 as a noninvasive maker in differentiating NASH
from NAFL, and its correlation with the disease severity.
2. Patients and methods
This study was conducted on 90 Egyptian individuals selected
from Internal Medicine and Hepatology outpatient clinics and
inpatient wards of Ain Shams University Hospitals (from Dec
2012 to Jul 2013).
They were classiﬁed into 3 groups:
 Group I: included 30 patients with NASH diagnosed by
abdominal ultrasonography and liver biopsy, with no his-
tory of consumption of alcohol or hepatotoxic drugs.
 Group II: included 30 patients with NAFL diagnosed by
abdominal ultrasonography and liver biopsy with no con-
sumption of alcohol or hepatotoxic drugs.
 Group III: included 30 age-matched healthy controls attend-
ing Blood Bank as blood donors or coming for pre-employ-
ment check up with normal abdominal ultrasonography,
normal aminotransferases, and no history of chronic liver
disease.
Inclusion criteria: patients with NASH and NAFLD on top
of Diabetes Mellitus (DM), obesity diagnosed by laboratory
tests, ultrasonography and liver biopsy.
Exclusion criteria: liver diseases other than fatty liver as:
chronic viral hepatitis, autoimmune hepatitis, liver cirrhosis,
hepatocellular carcinoma (HCC) patients and signiﬁcant alco-
holic consumption (more than 21 drinks/week in males and 14
drinks/week in females).
 A consent was taken from all individuals in this study. The
study was approved by the ethical committee of Ain Shams
University School of medicine. The work has been carried
out in accordance with the code of Ethics of the Wold Med-
ical Association (Declaration of Helsinki) for experiments
in humans.
Figure 1 Diagnostic performance of CK18 in diagnosis of
NASH. CK18 is highly speciﬁc (95%) and moderately sensitive
(76.7%) in the diagnosis of NASH.
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 Complete history taking and full physical examination,
including body mass index (BMI).
 Laboratory investigations including: complete blood count
(CBC), fasting blood sugar (FBS), glycated hemoglobin
(HA1C), Liver function tests: alanine transaminase
(ALT), aspartate transaminase (AST), Serum bilirubin,
serum albumin and prothrombin time (PT), lipid proﬁle
(cholesterol and triglycerides), Viral markers (HBsAg,
HBcAb, HCV Ab), Serum ferritin, immunoglobulins,
ANA, ASMA, anti LKM Ab and cytokeratin 18 level in
plasma by ELISA.
 Abdominal ultrasonography.
 Liver biopsy for patients of groups I and II.
 Fibroscan for control subjects to exclude liver ﬁbrosis.
2.1. Histopathological examination
Ultrasonography-guided liver biopsies were performed under
conscious sedation using a 16-gauge Klatskin needle. The
length of the histological specimens was no less than 2.5 cm.
All biopsy specimens were placed in 10% neutral buffered for-
malin solution for ﬁxation and embedded in parafﬁn blocks.
Serial sections (sectioned at 4-lm intervals) were concurrently
stained with Hematoxylin-Eosin and Masson’s trichrome. An
experienced pathologist blinded to the clinical data scored
the liver biopsies according to the NAFLD activity score
(NAS) in which:
1. Steatosis (S) was scored from 0 to 3 with a four-grade scor-
ing system from S0 to S3. S0: no steatosis or less than 5%,
S1: 5–33%, S2: > 33–66%, S3: > 66%).
2. Lobular inﬂammation was staged as: stage 0: no foci, stage
1: <2 foci, stage 2: 2–4 foci, stage 3: >4 foci per 200· ﬁeld.
3. Ballooning was staged as: stage 0: none, stage 1: few, stage
2: many ballooned cells.
4. Fibrosis was staged as: stage 0 with no ﬁbrosis, stage 1 as
perisinusoidal or periportal ﬁbrosis, stage 2 as perisinusoi-
dal and portal/periportal ﬁbrosis, stage 3 as bridging ﬁbro-
sis, stage 4 as cirrhosis.
The histological NAS was deﬁned as the sum of the scores
for steatosis (0–3), lobular inﬂammation (0–3), cell ballooning
(0–2), and ﬁbrosis (0–4). An NAS <3 corresponds to nonalco-
holic fatty liver (NAFL), 3–4 corresponds to borderline nonal-
coholic steatohepatitis (NASH), and a score P5 corresponds
to NASH [11].
2.2. Measurement of caspase-generated CK-18 fragments in the
blood
For all the patients in our study, a blood sample was taken
before liver biopsy. Blood samples were centrifuged at
2500·g for 10 min and serum aliquots were stored at
20 C until immediately before assay. All samples were ana-
lyzed in duplicate and blinded as to clinical status. Serum lev-
els of CK18-Asp396 were determined by commercially
available immunoassays according to the manufacturer’s
protocol.Concentrations of CK18-Asp396 were expressed in units
per liter (U/L) according to the manufacturer’s instructions.
The minimal detectable concentration in TPS ELISA is 6 U/
L. The assay has no ‘‘high-dose hook effect’’ up to 20,000 U/
L. The working range is 20–800 U/L. The 95th percentile for
apparently healthy individuals has been determined to 80 U/L.
3. Statistical analysis
Data was analyzed on an IBM personal computer, using statis-
tical package for special science (SPSS) software computer
program version 15.
 Data were described as mean ± Standard Deviation (SD)
for quantitative variables and as frequency and percentage
for qualitative variables. Independent Student t test was
used for comparison of quantitative variables among two
independent groups. Paired t test was used for comparison
of quantitative variables among groups. Chi-square test was
used for comparison of distribution of qualitative variables
among different groups. Correlation between continuous
variables was performed using Pearson correlation
coefﬁcient.
 Signiﬁcance level (P) value:
o P 6 0.05 is signiﬁcant (S).
o P< 0.01 is highly signiﬁcant (HS).
o P> 0.05 is insigniﬁcant (NS).
 ROC curve is a graphical plot which illustrates the perfor-
mance as its discrimination threshold is varied. It is created
by plotting the fraction of true positives out of the total
actual positives (sensitivity) vs. the fraction of false positives
out of the total actual negatives (speciﬁcity), at various
threshold settings.
4. Results and discussion
Descriptive data of the studied groups:
 This study included 90 Egyptian subjects who were divided
into 3 groups:
Figure 2 Logistic Regression Test showing positive prediction of
CK18 in diagnosis of NASH.
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included 24 (80 %) males and 6 (20%) females. Their ages ran-
ged from 20 to 74 with mean of 49.86 ± 14.15 years. Their
BMI ranged from 35 to 55 with mean of 42.38 ± 4.33. 23/30
of this group was diabetic; 15/30 was hypertensive and 14/30
had dyslipidemia.
Group II which included 30 patients with NAFL. This
group included 20 (66.67 %) males and 10 (33.33%) females.Table 1 Comparison between the 3 groups regarding the different
NASH no = 30 NAFLD no = 30
Mean ± SD Mean ± SD
FBS 120 ± 31 76 ± 10
HBA1C 6.9 ± 1.5 5.0 ± 0.5
Chol 232 ± 39 164 ± 31
TAG 140 ± 61 139 ± 43
LDL 170 ± 32 82 ± 16
AST 31 ± 19 28 ± 10
ALT 55 ± 30 53 ± 18
Ferritin 260 ± 104 294 ± 113
CK18 460 ± 279 167 ± 56
P1 = showing difference between group I (NASH) and group II (NAFL
P2 = showing difference between group II (NAFLD) and group III (con
P3 = showing difference between group I (NASH) and group III (contro
Chol: cholesterol, TAG: triglycerides, LDL: low density lipoprotein, CK
This table shows signiﬁcant difference between the NASH and NAFL gro
cholesterol, LDL and CK-18.Their ages ranged from 19 to 72 with mean of
47.69 ± 11.70 years. Their BMI ranged from 31 to 51 with
mean of 41.19 ± 4.24. 20/30 of this group was diabetics; 11/
30 was hypertensive and 7/30 had dyslipidemia.
Group III included 30 healthy controls: 22 (73.33 %) males
and 8 (26.67%) females. Their ages ranged from 21 to 80 with
mean of 47.69 ± 11.70 years. Their BMI ranged from 34 to 49
with mean of 42.96 ± 4.05. 22/30 of this group was diabetic; 8/
30 was hypertensive and 6/30 had dyslipidemia.
There is an urgent need to develop and validate a simple,
noninvasive test that accurately distinguishes NASH from
NAFLD and determines the stage of the disease [12].
In our study we evaluated the role of CK18 in diagnosing
NASH and its correlation with disease severity in a sample
of Egyptian patients.
In the current study we found statistically signiﬁcant differ-
ences between the 3 groups regarding plasma CK18 levels,
being highest in the NASH group (with mean ± SD:
460 ± 279 U/L) when compared with the group of NAFL
(mean ± SD: 167 ± 56 U/L) and the control group
(mean ± SD: 149 ± 57 U/L), with P value <0.001. On the
other hand there was no statistically signiﬁcant difference
between the NAFL group and the control group regarding
the plasma CK18 level with P value >0.05. Our results are
similar to Wieckowska et al., who found that CK18 couldparameters.
Controls no = 30 P value Post hoc test
Mean ± SD
80 ± 10 0.001 P1 = 0.001*
P2 = 0.126
P3 = 0.001*
5.0 ± 0.5 0.001 P1 = 0.001*
P2 = 1.000
P3 = 0.001*
176 ± 29 0.001 P1 = 0.001*
P2 = 0.342
P3 = 0.001*
144 ± 54 0.933 P1 = 0.157
P2 = 0.723
P3 = 0.311
81 ± 13 0.001 P1 = 0.001*
P2 = 1.000
P3 = 0.001*
27 ± 10 0.211 P1 = 0.933
P2 = 1.000
P3 = 0.811
53 ± 16 0.771 P1 = 0.872
P2 = 0.951
P3 = 0.713
269 ± 118 0.523 P1 = 0.561
P2 = 0.813
P3 = 0.722
149 ± 57 0.001 P1 = 0.001*
P2 = 0.872
P3 = 0.001*
D).
trols).
ls).
18: cytokeratin 18.
ups and the NASH and control groups regarding FBS, HA1C, total
Table 2 Correlation between CK-18 and NAS score in group
I and II.
CK-18
r P-value
Steatosis 0.441 0.015*
Lobular inﬂammation 0.457 0.011
Cell ballooning 0.509 0.004*
Fibrosis 0.317 0.045*
Mallory bodies 0.470 0.009*
NAS 0.746 0.001*
NAS: NAFLD activity score.
This table shows statistically signiﬁcant correlation between CK-18
and degree of steatosis, cell ballooning, ﬁbrosis, Mallory bodies and
NAS.
Table 3 Correlation between CK18 and other parameters in
all groups.
Groups CK-18
r P-value
Sex 0.213 0.699
BMI (body mass index) 0.799 0.001*
DM (diabetes mellitus) 0.506 0.0451*
Fasting blood glucose 0.792 0.001*
Glycosylated hemoglobin 0.810 0.001*
Hypertension 0.274 0.758
Dyslipidemia 0.458 0.049*
TAG 0.239 0.933
Cholesterol 0.823 0.001*
LDL 0.840 0.001*
AST 0.846 0.001*
ALT 0.804 0.001*
Ferritin 0.871 0.001*
This table shows statistically signiﬁcant correlation between CK-18
and BMI, DM, FBS, HA1C, dyslipidemia, total cholesterol, LDL,
AST, ALT and serum ferritin.
Cytokeratin 18 in NASH 45serve as an indicator of hepatic inﬂammation [13]. Similar
results were found in a study done by Feldstein et al. in chil-
dren, who found that CK18 levels were signiﬁcantly higher
in subjects with NASH compared with NAFL (322.1 U/
L ± 104.8 vs. 164.2 U/L ± 62, respectively; P< 0.001). They
also found that for every 10 U/L increase in CK18 levels, the
likelihood of having NASH increased by 70% [14].
This could be explained by the hepatocyte apoptosis
process which is one of the key components involved in the
progression of NAFL to NASH. This process is mediated by
the caspase activity. It is reported that Caspase 3 is activated
in NASH liver, which induce hepatocyte apoptosis and release
the CK18 fragments into the sera of NASH patients [15].Table 4 ROC curve showing diagnostic performance of CK18 in d
ROC curve
Cutoﬀ Sensitivity (%) Speciﬁcity (%)
>240 U/L 76.7 95.0
PPV: positive predictive value.
NPV: negative predictive value.In a study done by Gonsebatt et al., hepatic mRNA expres-
sion of CK18 has been reported to be up-regulated by oxida-
tive stress in mice; which could be another explanation for
the elevated levels of serum CK18 in NASH patients [16].
In the current study, there was positive statistically signiﬁ-
cant correlation between CK18 and BMI, DM, fasting blood
sugar, glycosylated hemoglobin (HBA1C), dyslipidemia, cho-
lesterol level, LDL, AST, ALT, ferritin and NAS. These results
go with the results of Miyasato et al. who found signiﬁcant
association between CK18 and BMI in the T2DM patients
with NAFLD [17].
In another study, CK-18 correlated most strongly with
ALT and adipose tissue insulin resistance (IR), less with stea-
tosis, lobular inﬂammation and ﬁbrosis, but not with balloon-
ing, BMI, metabolic syndrome or T2DM [18].
In the current study, there was positive correlation between
CK-18 and NAS score ballooning, Mallory bodies formation,
steatosis and ﬁbrosis in both the NASH and simple steatosis
groups.
Diab et al., showed a signiﬁcant positive correlation
between serum levels of fragmented CK18 and NAS in 65
NAFLD patients who had undergone bariatric surgery, and
a dramatic decrease in CK-18 levels 6 months following sur-
gery. These changes were greater in those subjects with NASH
and positively correlated with changes in transaminases, sug-
gesting that measuring CK-18 fragment levels in the blood
may be a useful test to monitor disease status postoperatively
[19].
The results of the current study goes with the results of the
study of Vuppalanchi et al., who found that changes in serum
levels of cytokeratin fragments appear to reﬂect changes in
liver histology in patients with NASH. They found that every
100-U/L decline in serum cytokeratin fragment (CK-18) level
was signiﬁcantly associated with overall histological improve-
ment (P< 0.001); resolution of NASH (P= 0.002); and
improvement of at least 1 point in steatosis grade, hepatocellu-
lar ballooning, and nonalcoholic fatty liver disease (NAFLD)
score (P less than .001 for all) [20].
In the current study, the ROC curve shows diagnostic per-
formance of CK18 with speciﬁcity (95%) and sensitivity
(76.7%) in the diagnosis of NASH with serum levels
>240 U/L. The Logistic Regression Test shows positive pre-
diction of CK18 in diagnosis of NASH.
Although Younossi et al. proved the independency of
CK18 fragments as a predictor of NASH, their results suggest
that CK18 fragments have sufﬁcient-to-excellent diagnostic
accuracy for the detection (or exclusion) of NASH in the set-
ting of NAFLD [21]. As a consequence, Younossi and cowork-
ers have developed a test (NASH diagnostics) based on four
ELISA assays (cleaved and intact CK18 added to serum
adiponectin, and serum resistin) to form a simple diagnostic
marker for NASH [21].iagnosis of NASH.
PPV NPV Accuracy
88.5 89.1 87.12
46 M.M. Maher et al.In another study done by Feldstein et al., the performance
of CK18 level for the diagnosis of NASH was excellent with an
area under the Receiver Operating Characteristics curve of
0.933 [14] (Figs. 1 and 2 and Tables 1–4).
5. Conclusion
Measurement of CK18 seems to be promising as screening,
diagnostic and staging biomarker in NASH.
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